TET2 deficiency inhibits mesoderm and hematopoietic differentiation in human embryonic stem cells

Stem Cells

Volumn 32, Issue 8, 2014, Pages 2084-2097

  Langlois, Thierry ^a,b,c   Da Costa Reis Monte Mor, Barbara ^a,b,c   Lenglet, Gaëlle ^a,b,c   Droin, Nathalie ^a,b,c   Marty, Caroline ^a,b,c   Le Couédic, Jean Pierre ^a,b,c   Almire, Carole ^a,c,d,e   Auger, Nathalie ^b   Mercher, Thomas ^a,b,c   Delhommeau, François ^a,c,d,e   Christensen, Jesper ^f,g   Helin, Kristian ^f,g   Debili, Najet ^a,b,c   Fuks, François ^h   Bernard, Olivier A ^a,b,c   Solary, Eric ^a,b,c   Vainchenker, William ^a,b,c   Plo, Isabelle ^a,b,c  

^a INSERM   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d SORBONNE UNIVERSITÉ   (France)

^e HÔPITAL SAINT ANTOINE   (France)

^f UNIVERSITY OF COPENHAGEN   (Denmark)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

^h FREE UNIVERSITY OF BRUSSELS   (Belgium)

Author keywords

Hematopoiesis; hES; NANOG; TET2

Indexed keywords

MEMBRANE PROTEIN; SHORT HAIRPIN RNA; TEN ELEVEN TRANSLOCATION 2; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; HOMEODOMAIN PROTEIN; NANOG PROTEIN, HUMAN; ONCOPROTEIN; TET2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CLONING; EMBRYO; EMBRYONIC STEM CELL; ENDODERM; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESODERM; METHYLATION; NEUROECTODERM; PLURIPOTENT STEM CELL; PROMOTER REGION; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; CYTOLOGY; FLOW CYTOMETRY; GENE SILENCING; HEMATOPOIESIS; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL LINE; CHROMATIN IMMUNOPRECIPITATION; DNA-BINDING PROTEINS; EMBRYONIC STEM CELLS; FLOW CYTOMETRY; GENE KNOCKDOWN TECHNIQUES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HOMEODOMAIN PROTEINS; HUMANS; MESODERM; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84904413135     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1718     Document Type: Article

References (50)

1. Baylin, S,. DNA methylation and epigenetic mechanisms of carcinogenesis. Dev Biol (Basel). 2001; 106: 85-87; discussion 143-160.
2. Robertson KD,. DNA methylation and chromatin-Unraveling the tangled web. Oncogene 2002; 21: 5361-5379.
3. Surani MA, Hayashi K, Hajkova P,. Genetic and epigenetic regulators of pluripotency. Cell 2007; 128: 747-762.
4. Ko M, Huang Y, Jankowska AM, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839-843.
5. Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009; 324: 930-935.
6. He YF, Li BZ, Li Z, et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011; 333: 1303-1307.
7. Ito S, Shen L, Dai Q, et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011; 333: 1300-1303.
8. Xu Y, Wu F, Tan L, et al. Genome-wide regulation of 5hmC, 5mC, and gene expression by Tet1 hydroxylase in mouse embryonic stem cells. Mol Cell 2011; 42: 451-464.
9. Cortellino S, Xu J, Sannai M, et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 2011; 146: 67-79.
10. Guo JU, Su Y, Zhong C, et al. Hydroxylation of 5-methylcytosine by TET1 promotes active DNA demethylation in the adult brain. Cell 2011; 145: 423-434.
11. Ito S, D'Alessio AC, Taranova OV, et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 2010; 466: 1129-1133.
12. Koh KP, Yabuuchi A, Rao S, et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 2011; 8: 200-213.
13. Kriaucionis S, Heintz N,. The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain. Science 2009; 324: 929-930.
14. Wossidlo M, Nakamura T, Lepikhov K, et al. 5-Hydroxymethylcytosine in the mammalian zygote is linked with epigenetic reprogramming. Nat Commun 2011; 2: 241.
15. Gu TP, Guo F, Yang H, et al. The role of Tet3 DNA dioxygenase in epigenetic reprogramming by oocytes. Nature 2011; 477: 606-610.
16. Ficz G, Branco MR, Seisenberger S, et al. Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation. Nature 2011; 473: 398-402.
17. Pastor WA, Pape UJ, Huang Y, et al. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 2011; 473: 394-397.
18. Williams K, Christensen J, Pedersen MT, et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 2011; 473: 343-348.
19. Wu H, D'Alessio AC, Ito S, et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 2011; 473: 389-393.
20. Dawlaty MM, Breiling A, Le T, et al. Combined deficiency of tet1 and tet2 causes epigenetic abnormalities but is compatible with postnatal development. Dev Cell 2013; 24: 310-323.
21. Dawlaty MM, Ganz K, Powell BE, et al. Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development. Cell Stem Cell 2011; 9: 166-175.
22. Quivoron C, Couronne L, Della Valle V, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. Cancer Cell 2011; 20: 25-38.
23. Abdel-Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144-147.
24. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289-2301.
25. Kosmider O, Gelsi-Boyer V, Ciudad M, et al. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 2009; 94: 1676-1681.
26. Langemeijer SM, Kuiper RP, Berends M, et al. Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 2009; 41: 838-842.
27. Tefferi A, Levine RL, Lim KH, et al. Frequent TET2 mutations in systemic mastocytosis: Clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009; 23: 900-904.
28. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010; 18: 553-567.
29. Pronier E, Almire C, Mokrani H, et al. Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulo-monocytic differentiation of human hematopoietic progenitors. Blood 2011; 118: 2551-2555.
30. Li Z, Cai X, Cai CL, et al. Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 2011; 118: 4509-4518.
31. Moran-Crusio K, Reavie L, Shih A, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 2011; 20: 11-24.
32. Busque L, Patel JP, Figueroa ME, et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat Genet 2012; 44: 1179-1181.
33. Klimchenko O, Mori M, Distefano A, et al. A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cell-derived primitive hematopoiesis. Blood 2009; 114: 1506-1517.
34. Takayama N, Nishikii H, Usui J, et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 2008; 111: 5298-5306.
35. Plo I, Nakatake M, Malivert L, et al. JAK2 stimulates homologous recombination and genetic instability: Potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008; 112: 1402-1412.
36. Vodyanik MA, Yu J, Zhang X, et al. A mesoderm-derived precursor for mesenchymal stem and endothelial cells. Cell Stem Cell 2010; 7: 718-729.
37. Vella P, Scelfo A, Jammula S, et al. Tet proteins connect the O-linked N-acetylglucosamine transferase Ogt to chromatin in embryonic stem cells. Mol Cell 2013; 49: 645-656.
38. Wang T, Wu H, Li Y, et al. Subtelomeric hotspots of aberrant 5-hydroxymethylcytosine-mediated epigenetic modifications during reprogramming to pluripotency. Nat Cell Biol 2013; 15: 700-711.
39. Vodyanik MA, Thomson JA, Slukvin II,. Leukosialin (CD43) defines hematopoietic progenitors in human embryonic stem cell differentiation cultures. Blood 2006; 108: 2095-2105.
40. Teo AK, Arnold SJ, Trotter MW, et al. Pluripotency factors regulate definitive endoderm specification through eomesodermin. Genes Dev 2011; 25: 238-250.
41. Yu P, Pan G, Yu J, et al. FGF2 sustains NANOG and switches the outcome of BMP4-induced human embryonic stem cell differentiation. Cell Stem Cell 2011; 8: 326-334.
42. Doege CA, Inoue K, Yamashita T, et al. Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2. Nature 2012; 488: 652-655.
43. Costa Y, Ding J, Theunissen TW, et al. NANOG-dependent function of TET1 and TET2 in establishment of pluripotency. Nature 2013; 495: 370-374.
44. Klimchenko O, Di Stefano A, Geoerger B, et al. Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood 2011; 117: 3065-3075.
45. Ruzov A, Tsenkina Y, Serio A, et al. Lineage-specific distribution of high levels of genomic 5-hydroxymethylcytosine in mammalian development. Cell Res 2011; 21: 1332-1342.
46. Tesar PJ, Chenoweth JG, Brook FA, et al. New cell lines from mouse epiblast share defining features with human embryonic stem cells. Nature 2007; 448: 196-199.
47. Daheron L, Opitz SL, Zaehres H, et al. LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells 2004; 22: 770-778.
48. Szwagierczak A, Bultmann S, Schmidt CS, et al. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 2010; 38: e181.
49. Szwagierczak A, Bultmann S, Schmidt CS, et al. Sensitive enzymatic quantification of 5-hydroxymethylcytosine in genomic DNA. Nucleic Acids Res 2010; 38: e181.
50. Schaub FX, Looser R, Li S, et al. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms. Blood 2010; 115: 2003-2007.